Special Issue

Uropathogens—Antibiotic Resistance and Alternative Therapies, 2nd Edition

Message from the Guest Editors

The increase in antibiotic resistance and the appearance of multi-drug resistant (MDR) pathogens in UTIs is associated with high rates of inadequate antibiotic empirical therapies. An understanding of regional differences concerning uropathogens responsible for UTIs and their antibiotic susceptibility is crucial for public health and important in empirical therapy to promote the proper use of existing chemotherapeutics. In addition, there is a urgent priority to find new antimicrobial agents, alternatives to antibiotics or additional prophylactic strategies to control UTIs, including biofilm formation in the urinary tract and on urinary catheters. Among these innovative agents, phytochemicals, preventive vaccines, probiotics, bacteriophages and nanoparticles seem to be the most promising. Similar to the first edition of this Special Issue, manuscripts presenting all aspects of the challenges of drug resistance to uropathogens, as well as innovative approaches for the treatment of UITs, are welcome.

Guest Editors

Dr. Barbara Kot

Institute of Biological Sciences, Faculty of Exact and Natural Sciences, Siedlce University of Natural Sciences and Humanities, B. Prusa 14, 08-110 Siedlce, Poland

Dr. Piotr Szweda

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/123412

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

